ONSOLIS

Type: Product
Name: ONSOLIS
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

BioDelivery Sciences Appoints Charles J. Bramlage -2-

undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.BDSI(R) and BEMA(R) are registered trademarks of BioDelivery Sciences ... [Published Scottrade - Jul 22 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

BioDelivery Sciences Announces Completion of Patient Enrollment in its Initial Phase 3 Trial of Clonidine..

/PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN).The ... [Published ADVFN India - Jun 26 2014]
First reported May 08 2014 - Updated May 09 2014 - 1 reports

BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

/PRNewswire/ -- BioDelivery Sciences International, Inc. ( BDSI ) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2014 Health Care Conference.  The presentation is scheduled ... [Published Yahoo! Finance - May 08 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Meda and Valeant Terminates Joint Ventures

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) has reached an agreement with Valeant to terminate the companies’ joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates ... [Published Business Wire Health News - Apr 07 2014]

Quotes

...Andrew Finn , Executive Vice President of Product Development.  "The expeditious enrollment of this study in part illustrates the significant unmet need that exists for new treatment options for patients suffering from painful diabetic neuropathy.  Based on the enrollment of this trial, and assuming no additional patients will be required following the interim analysis, we should have top-line study results by the end of the year."

More Content

All (5) | News (3) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
BioDelivery Sciences Appoints Charles J. Bramla... [Published Scottrade - Jul 22 2014]
BioDelivery Sciences Announces Completion of Pa... [Published ADVFN India - Jun 26 2014]
BioDelivery Sciences to Present at the Bank of ... [Published Yahoo! Finance - May 08 2014]
Meda and Valeant terminates joint ventures [Published GlobeNewswire: Advertising News - Apr 07 2014]
Meda and Valeant Terminates Joint Ventures [Published Business Wire Health News - Apr 07 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Meda and Valeant Terminates Joint Ventures [Published Business Wire Health News - Apr 07 2014]
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) has reached an agreement with Valeant to terminate the companies’ joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates ...
1

Press Releases

sort by: Date | Relevance
Meda and Valeant terminates joint ventures [Published GlobeNewswire: Advertising News - Apr 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.